vaccine development News
-
Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants
The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to create new vaccines at an unprecedented speed. Despite the success of current vaccines in ...
-
Micron receives contract from CDC to manufacture IRV microneedle patches
Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to manufacture IRV microneedle patches for future clinical evaluation. Micron and CDC have been collaborating on the development of the IRV microneedle patch for several years. Preclinical studies of the IRV vaccine, developed by the CDC, delivered using Micron’s ...
-
CD BioGlyco Provides Integrated Solutions for Glycoprotein Vaccine Design
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are critical in viral attachment and cell fusion, and investigation of these proteins may provide ...
By CD BioGlyco.
-
We are looking for a Clinical Project Manager
Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...
-
SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic. The US FDA has approved Pfizer and ...
By CD BioGlyco.
-
Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like complexes that can ...
-
Alfa Chemistry Excels in mRNA Vaccine Development, Production, Optimization, and Quality Control
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. Alfa Chemistry, a renowned scientific research ...
-
Study from Scripps using SpyTag/SpyCatcher for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development
A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses. ...
-
The biotechnology company Zendal launches a subsidiary exclusively for probiotics
The Galician biotechnology group Zendal, known as CZ-Biofabri until the end of last year, has just announced the launch of a new subsidiary called Zinereo Pharma, which will focus entirely on the manufacturing of probiotics. This new company was created after Biofabri split up into two companies specialized in human health: Biofabri, specialized in vaccine development and manufacturing, and the ...
-
Virica Biotech: Enabling Vaccine Development to Fight Against COVID-19
As the world deals with COVID-19, now officially deemed a pandemic, many groups are racing against the clock to develop vaccines against the novel coronavirus. The development and manufacturing of effective vaccines is a laborious and challenging task for a variety of reasons. In the pandemic situation that we and our loved ones are facing today, creating, manufacturing, testing, and delivering ...
-
Visit of His Majesty the King of the Belgians Philippe and Her Majesty the Queen of the Belgians Mathilde to Afrigen Biologics
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
By eTheRNA
-
Thermo Fisher Scientific Unveils Gibco ExpiSf System, First Ever Chemically Defined Insect Protein Expression System
Historically, undefined insect media components such as yeastolate have made it challenging to achieve consistent results and protein yields across multiple experiments. These factors can significantly slow vaccine development at a time when manufacturers are under pressure to develop vaccines faster and more efficiently. Focused on removing barriers to vaccine development and production, Thermo ...
-
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida
GRAND FORKS, N.D. – October 3, 2013 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has closed a $14M Series B financing. Participating investors included new investor RusnanoMedInvest (RMI) and current investor Domain Associates. The proceeds from this financing will be used to conduct an ongoing Phase 2 ...
-
Dengue Virus-Like Particles launched
The Native Antigen Company Limited (‘NAC’: Oxford, UK) announces the launch of a new range of Dengue Virus-Like Particles incorporating products for all four Dengue serotypes. Virus-Like Particles (VLPs) represent an increasingly important technology for use in vaccine development and serology. VLPs consist of protein shells comprising outer proteins specific to the virus in ...
-
NovaDigm Therapeutics’ Chief Executive Officer, Timothy Cooke, Appointed to the National Vaccine Advisory Committee
GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that Timothy Cooke, Ph.D., NovaDigm’s Chief Executive Officer, has been appointed to a four-year term on the National Vaccine Advisory Committee (NVAC) by Karen B. DeSalvo, M.D., MPH, MSc, Acting Assistant Secretary for Health at the U.S. ...
-
Abera’s New Vaccine Platform Validated In Published PHD Thesis
Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the ...
-
Abera Initiates the Development of a New Vaccine Candidate Through a Collaboration Agreement With American University
Abera Bioscience AB is a biotechnology company that develops vaccine candidates based on patented vaccine platforms. The latest vaccine platform makes it possible to produce single, or multiple, antigens in so-called protein bodies. Antigens are the pathogen-specific components of vaccines that elicit immune responses. Protein bodies are nano-sized protein particles. The company is now entering ...
-
Abera Receives grant from Vinnova
Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the company’s platforms to attract funding from the ...
-
BOC Sciences Becomes the Largest PseudoUridine Supplier in the World
BOC Sciences recently announces that its annual yield of pseudoUridine has reached more than 500 kilograms, which indicates that this US-based chemical and pharmaceutical company has become the largest supplier of pseudoUridine in the world. Currently, due to the severe situation of the COVID-19 pandemic, the global need for vaccines is still huge. Under this circumstance, BOC Sciences has ...
By BOC Sciences
-
NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio with Three New Antigens via Series of Rights Acquisitions
GRAND FORKS, ND – June 10, 2014 – NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has acquired the rights, in four separate transactions, to three well-studied Candida vaccine antigens, significantly bolstering the Company’s Candida vaccine pipeline. These three antigens are in addition to the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you